Core Viewpoint - Xirui (02507) has experienced a significant decline of over 5%, dropping nearly 30% from its monthly high, with a current trading price of 53.3 HKD and a transaction volume of 490 million HKD [1] Financial Performance - For the first half of the year, Xirui reported revenue of 594 million USD, representing a year-on-year growth of 25.1% [1] - The gross profit reached 215 million USD, showing a year-on-year increase of 31.5% [1] - Net profit stood at 64.9966 million USD, reflecting a substantial year-on-year growth of 82.5% [1] - The growth in performance is attributed to an increase in aircraft deliveries, higher product pricing, and the ongoing expansion of Xirui's service business [1] - The operating profit margin for the first half of 2025 reached 14.1%, an increase of 430 basis points year-on-year, positioning the company among the industry leaders [1] Market Reaction - On August 22, the Hang Seng Index Company announced its quarterly review results, with changes to be implemented after market close on September 5 and effective from September 8 [1] - Xirui was removed from the Hang Seng Composite Index, raising market concerns about its potential removal from the Hong Kong Stock Connect list in September [1]

Group 1 - The core viewpoint of the article highlights that Xirui (02507) has experienced a significant decline of over 5%, with a nearly 30% drop from its monthly high, currently trading at 53.3 HKD with a transaction volume of 490 million HKD [1] - Xirui reported mid-term results showing a revenue of 594 million USD for the first half of the year, representing a year-on-year growth of 25.1% [1] - The company's gross profit reached 215 million USD, up 31.5% year-on-year, and net profit was 64.9966 million USD, reflecting an 82.5% increase compared to the previous year [1] Group 2 - The growth in performance is attributed to an increase in aircraft deliveries, higher product pricing, and the continuous expansion of Xirui's service business [1] - As of the first half of 2025, the operating profit margin reached 14.1%, which is a year-on-year improvement of 430 basis points, placing the company among the industry leaders [1] - On August 22, the Hang Seng Index Company announced its quarterly review results, indicating that Xirui will be removed from the Hang Seng Composite Index, raising market concerns about its potential removal from the Hong Kong Stock Connect list in September [1]

Group 1 - On August 26, 2025, the top three companies by trading volume in the Southbound Stock Connect were Yingfu Fund (02800) with a trading volume of 5.01 billion, SMIC (00981) with 3.86 billion, and Alibaba-W (09988) with 3.29 billion [1] - In the Southbound Stock Connect for Shenzhen-Hong Kong, the top three companies were Alibaba-W (09988) with a trading volume of 2.19 billion, SMIC (00981) with 1.95 billion, and Tencent Holdings (00700) with 1.81 billion [1] Group 2 - The top active companies in the Southbound Stock Connect (Hong Kong) included Yingfu Fund (02800) with a net buy of 4.997 billion, Alibaba-W (09988) with a net buy of 448 million, and Tencent Holdings (00700) with a net buy of 911 million [2] - In the Southbound Stock Connect (Shenzhen), Alibaba-W (09988) had a net buy of 897 million, while SMIC (00981) and Tencent Holdings (00700) had net sells of 275 million and 240 million respectively [2]

Core Viewpoint - Jin Jing New Energy (01783) has seen a significant increase of over 7%, currently trading at 8.86 HKD with a transaction volume of 16.2456 million HKD, following its inclusion in the Hang Seng Composite Index [1] Group 1 - The Hang Seng Index Company announced its semi-annual index adjustment results on August 22, which included Jin Jing New Energy as a constituent stock [1] - The adjustment will take effect after the market closes on September 5 and will be effective from September 8 [1] - Analysts from UBS, CICC, and Shenwan Hongyuan have predicted that Jin Jing New Energy is likely to be included in the Hong Kong Stock Connect list [1] Group 2 - The inclusion in the index is expected to attract more southbound capital and passive funds, such as index funds, leading to a significant increase in short-term liquidity for Jin Jing New Energy [1]

Group 1 - The core point of the article is that Xixiangfeng Group (02473) has seen a stock price increase of over 4% after being included in the Hang Seng Composite Index, with a reported price of 8.38 HKD and a trading volume of 13.14 million HKD [1] - The inclusion in the Hang Seng Composite Index will take effect after the market closes on September 5, 2023, and will be effective from September 8, 2023, which may lead to adjustments in the Hong Kong Stock Connect investment scope [1] - According to Huatai Securities research, Xixiangfeng Group is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] Group 2 - For the six months ending June 30, 2025, Xixiangfeng Group reported a revenue of 769 million RMB, representing a year-on-year increase of 16.78% [1] - The net profit attributable to shareholders was 22.486 million RMB, which is a year-on-year increase of 14.23%, with basic earnings per share of 1.45 cents [1] - The revenue growth is primarily attributed to a significant increase in the company's direct retail business in the automotive sector and the expansion of its self-operated sales network [1]

Core Viewpoint - The company, 喜相逢集团 (02473), has seen a significant increase in its stock price following its inclusion in the Hang Seng Composite Index, which is set to take effect on September 8, 2023. This inclusion is expected to enhance the company's visibility and liquidity in the market [1]. Group 1: Stock Performance - The stock price of 喜相逢集团 rose by over 4%, with a current price of 8.38 HKD and a trading volume of 13.14 million HKD [1]. - As of the latest report, the stock has increased by 3.97% [1]. Group 2: Index Inclusion - On August 22, the Hang Seng Index Company announced the quarterly review results, confirming that 喜相逢集团 will be included in the Hang Seng Composite Index, effective after market close on September 5, 2023 [1]. - The inclusion is anticipated to lead to adjustments in the Hong Kong Stock Connect investment scope, as the company meets various criteria such as market capitalization, liquidity, and listing duration [1]. Group 3: Financial Performance - For the six months ending June 30, 2025, the company reported revenues of 769 million RMB, reflecting a year-on-year increase of 16.78% [1]. - The net profit attributable to shareholders was 22.486 million RMB, up 14.23% year-on-year, with basic earnings per share of 1.45 cents [1]. - The revenue growth is primarily attributed to a significant increase in the company's direct retail automotive business and the expansion of its self-operated sales network [1].

消息面上，8月22日盘后，恒生指数公司公布了其定期的半年度指数调整结果，其中晋景新能获纳入恒 生综合指数成分股，变动将于9月5日收市后实施并于9月8起生效。此前，瑞银、中金及申万宏源预计晋 景新能有望纳入港股通名单标的。分析人士指出，入通后晋景新能有望获得更多南向资金的关注、青 睐，以及被动资金如指数基金的增配，短期流动性便将显著提升。 智通财经APP获悉，晋景新能(01783)再涨超7%，截至发稿，涨7%，报8.86港元，成交额1624.56万港 元。 ...

Group 1: Top Net Buy/Sell Companies - The top net buy company is China Life (2628.HK) with a net buy amount of 4.327 billion CNY, representing an increase of 174,625,000 shares[8] - The second highest net buy is the Tracker Fund of Hong Kong (2800.HK) with a net buy amount of 3.143 billion CNY, increasing by 121,631,600 shares[8] - The top net sell company is Kuaishou (1024.HK) with a net sell amount of -1.734 billion CNY, decreasing by 23,156,028 shares[9] Group 2: Industry Distribution of Net Buy/Sell - Financial sector shows significant net buying, led by China Life and AIA Group (1299.HK) with net buys of 4.327 billion CNY and 1.433 billion CNY respectively[8] - The consumer discretionary sector also sees strong net buying, particularly from Alibaba (9988.HK) with a net buy of 2.213 billion CNY[8] - The technology sector has mixed results, with Tencent (0700.HK) showing a net buy of 2.538 billion CNY while Kuaishou (1024.HK) shows a net sell[9] Group 3: Active Stocks - Tencent (0700.HK) is the most active stock with a total trading volume of 3.527 billion CNY and a net buy of 1.618 billion CNY[19] - Meituan (3690.HK) also shows high activity with a trading volume of 2.744 billion CNY and a net buy of 789 million CNY[19] - The Tracker Fund of Hong Kong (2800.HK) had a trading volume of 4.148 billion CNY but a significant net sell of -4.130 billion CNY[22]

丨证券研究报告丨 投资策略丨点评报告 [Table_Title] 恒生系列指数季度检讨结果公布，港股通名单或 随之调整——"重估牛"系列之"入通"策略 报告要点 分析师及联系人 [Table_Author] 戴清 SAC：S0490524010002 SFC：BTR264 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_Summary] 8 月 22 日，恒生指数公司发布了截至 2025 年 6 月 30 日的恒生指数系列季度检讨结果，恒生 指数、恒生中国企业指数，以及恒生综合指数等指数的成分股发生变化。 纳入恒生综合指数的 个股有望进入港股通，根据我们对于 2022 年至 2025 年 3 月"入通"的全样本进行统计，纳入 港股通前个股有望实现一定涨幅，建议持续关注。 [Table_Title 恒生系列指数季度检讨结果公布，港股通名单 2] 或随之调整——"重估牛"系列之"入通"策略 [Table_Summary2] 事件描述 8 月 22 日，恒生指数公司发布了截至 2025 年 6 月 30 日的恒生指数系列季度检讨结果，恒生 指数、恒生中国 ...

Core Viewpoint - The continuous policy support for traditional Chinese medicine (TCM) is reshaping the domestic TCM development landscape, providing structural upgrade opportunities for companies like Kangchen Pharmaceutical [1][15]. Policy Environment - Recent top-level design documents, including various opinions and plans, have been issued to promote the innovation and development of TCM [1]. - The State Council's recent opinion emphasizes quality traceability, intelligent transformation, and technological innovation as core tasks for the TCM industry [1]. Company Performance - Kangchen Pharmaceutical has seen its intrinsic value recognized by the market, with a stock price increase of 119.89% in 2024 and a further rise of 85.99% by August 22, 2025 [1][3]. - The company reported a revenue of 1.569 billion RMB for the first half of 2025, a year-on-year increase of 23.7%, and a net profit of 498 million RMB, up 24.6% [4]. Shareholder Returns - The company is actively returning value to shareholders through high dividends, stock buybacks, and management's continuous share purchases, which have boosted market confidence [3][6]. - Kangchen Pharmaceutical's interim dividend for 2025 is set at 0.33 HKD per share, with a payout ratio exceeding 51% [4]. Market Position - As of August 22, 2025, Kangchen Pharmaceutical's market capitalization reached 12.448 billion HKD, positioning it favorably for potential inclusion in the Hong Kong Stock Connect [3][7]. - The company's current price-to-earnings ratio (TTM) is 11.47, which is below the average of 23.40 for the industry, despite having the highest return on equity (ROE) among peers [5]. Growth Drivers - The renal medicine segment, particularly the unique product Urine Toxin Clear Granules, has driven significant revenue growth, achieving a 28% increase in sales [10]. - The company is expanding its product pipeline, including new drugs for chronic kidney disease (CKD) and related conditions, supported by strategic partnerships and academic collaborations [11][12]. Future Outlook - The anticipated inclusion in the Hong Kong Stock Connect is expected to enhance liquidity and attract mainland capital, further driving stock performance [7][9]. - The overall market sentiment towards the pharmaceutical sector is improving, with expectations of continued valuation recovery and growth potential for quality companies like Kangchen Pharmaceutical [15].